Physician profile
Gregory Alan Dean
NPI 1568430437
$4,096.84
in general payments reported to CMS, 2019-2025
31 companies · $742 in 2025
The $742 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $336 · 2021: $203 · 2022: $523 · 2023: $991 · 2024: $867 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.11 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $454.90 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $259.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.03 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $199.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $170.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $153.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $112.02 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.49 | 2022-2023 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $108.90 | 2019-2023 | Xarelto |
| Organogenesis INC. | $69.28 | 2024-2025 | Puraply Wound Matrix, Apligraf |
| Kowa Pharmaceuticals America, INC. | $63.95 | 2019-2022 | |
| Mimedx Group, INC. | $54.87 | 2025 | |
| Glaxosmithkline, LLC. | $48.06 | 2023-2024 | Shingrix, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.74 | 2020 | |
| Kerecis Limited | $42.56 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Lundbeck LLC | $36.88 | 2020-2021 | |
| Viatris Specialty LLC | $35.35 | 2025 | Yupelri |
| Amarin Pharma, INC. | $32.22 | 2020 | |
| Mylan Specialty L.P. | $30.00 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.96 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $18.06 | 2024 | Voquezna |
| Medtronic, INC. | $16.70 | 2021 | |
| Abbott Laboratories | $16.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.85 | 2024 | Oxlumo |
| Vertex Pharmaceuticals Incorporated | $14.96 | 2025 | |
| Allergan, INC. | $14.13 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.94 | 2019 | |
| Genentech USA, INC. | $12.25 | 2020 | |
| Biodelivery Sciences International, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.